論文 - 詳細
| RRC ID | 72502 |
|---|---|
| 著者 | Han CK, Lee WF, Hsu CJ, Huang YL, Lin CY, Tsai CH, Huang CC, Fong YC, Wu MH, Liu JF, Tang CH. |
| タイトル | DPP4 reduces proinflammatory cytokine production in human rheumatoid arthritis synovial fibroblasts. |
| ジャーナル | J Cell Physiol |
| Abstract |
Rheumatoid arthritis (RA) is an autoimmune disorder that is characterized by increasing levels of proinflammatory cytokines. The ubiquitous enzyme dipeptidyl peptidase-4 (DPP4, also known as CD26) regulates different immune disorders, although the effects of DPP4 in RA are uncertain. Here, we found lower levels of DPP4 in RA synovial tissues compared with normal tissues. DPP4 levels were also lower in a rat collagen-induced arthritis model than in control (healthy) rats. Overexpression of DPP4 or exogenous treatment of RA synovial fibroblasts with DPP4 reduced levels of proinflammatory interleukin (IL)-1β, IL-6, and IL-13, and increased anti-inflammatory IL-10 synthesis, while DPP4 inhibitors sitagliptin and vildagliptin increased proinflammatory cytokine production, indicating an enhanced risk of RA development. The evidence suggests that increasing DPP4 expression is a novel strategy for RA disease. |
| 巻・号 | 236(12) |
| ページ | 8060-8069 |
| 公開日 | 2021-12-1 |
| DOI | 10.1002/jcp.30494 |
| PMID | 34192347 |
| MeSH | Animals Arthritis, Rheumatoid / drug therapy* Arthritis, Rheumatoid / metabolism Cytokines / drug effects* Cytokines / metabolism Dipeptidyl Peptidase 4* / metabolism Dipeptidyl Peptidase 4* / pharmacology Fibroblasts / drug effects* Fibroblasts / metabolism Humans Inflammation / drug therapy Inflammation / metabolism Synovial Membrane / drug effects Synovial Membrane / metabolism |
| IF | 5.546 |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | Patent(IFI CLAIMS) |
| 各媒体での言及数の合計 | 1 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| ヒト・動物細胞 | MH7A(RCB1512) |